China Medical System Holdings Secures Exclusive Rights to Atom Therapeutics’ Gout Drug ABP-671
China Medical System Holdings (CMS; HKG: 0867) has entered into a licensing agreement with compatriot...
China Medical System Holdings (CMS; HKG: 0867) has entered into a licensing agreement with compatriot...
Swiss pharmaceutical giant Novartis (NYSE: NVS) has entered into a global license and collaboration agreement...
Belgium based UCB (EBR: UCB) is fulfilling its commitment to enhance attention to innovative products...
Shanghai-based Minghui Pharmaceutical, a late-stage biopharmaceutical company specializing in immunology and oncology, has announced positive...
The National Health Commission (NHC) has released the “Pilot Work Plan for Expanding the Wholly...
China-based Hua Medicine (HKG: 2552) has announced the successful completion of a Phase Ia study...
Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA: 688373) has announced that its Phase III study for...
Singapore-based healthcare private equity firm CBC Group and Mubadala Investment Company, a global investment company...
Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary, Simcere Zaiming, has announced the initiation of a...
China-based innovative drug developer Hua Medicine (HKG: 2552), with operations in the US and Hong...
China-based Sunflower Pharmaceutical Group Co., Ltd. (SHE: 002737) is poised to establish a joint laboratory...
China-based Simcere Pharmaceutical Group Limited (HKG: 2096) has announced receiving marketing approval from the National...
Shanghai Pharmaceuticals Holding Co., Ltd. (HKG: 2607, SHA: 601607) has announced the completion of data...
Affinity (Shanghai), the parent company of Shanghai Affinity Biopharmaceutical Co., Ltd., has reportedly raised upwards...
China-based nucleic acid drug developer Suzhou Abogen Biosciences and Ruijin Hospital, a comprehensive Class 3A...
Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the initiation of commercial supply of its...
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541), a China-based biopharmaceutical company, has announced receiving approval from...
On November 30th, Healthgen Biotechnology Corp. announced a significant research outcome at the 9th Pharmaceutical...
Shanghai Cell Therapy Group Co., Ltd., a leading player in China’s cellular medical health sector,...
Nanjing Leads Biolabs Co., Ltd., a clinical-stage biopharmaceutical company focused on developing innovative therapies for...